The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b study of the OxPhos inhibitor ME-344 in combination with bevacizumab in refractory metastatic colorectal cancer.
 
Patrick M Boland
Consulting or Advisory Role - Bayer; Guardant Health; Merck; Pfizer; Taiho Oncology
Research Funding - Caris Life Sciences (Inst); Compass Therapeutics (Inst); Compass Therapeutics (Inst); Merck (Inst); Processa Pharmaceuticals (Inst)
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche
Consulting or Advisory Role - 3T BioSciences; Bayer; BMS; Fulgent Genetics; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono
 
Mike Cusnir
Speakers' Bureau - Guardant Health; Sirtex Medical
 
Vaia Florou
Consulting or Advisory Role - Deciphera; Incyte
 
Michael J. Pishvaian
Stock and Other Ownership Interests - Perthera; Targeting Resistance in Cancer Cooperative; Tumor Board Tuesday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; IDEAYA Biosciences; Merck; Merus; Novartis; Pfizer; Seagen; TriSalus Life Sciences
Research Funding - Actuate Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); MEI Pharma (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); RenovoRx (Inst); RenovoRx (Inst); Repare Therapeutics (Inst); Seagen (Inst); Takeda (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Perthera patient matching algorithm; Use patent for veliparib and FOLFOX
Travel, Accommodations, Expenses - Astellas Pharma; RenovoRx
 
Deirdre J. Cohen
Consulting or Advisory Role - Astellas Pharma
Speakers' Bureau - Guardant Health
Research Funding - Eisai (Inst); Merck (Inst); Viome (Inst)
 
Kristen Keon Ciombor
Consulting or Advisory Role - Exelixis; Incyte; Lilly; Merck; Personalis; Pfizer; Replimune; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Incyte (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Nucana (Inst); Onyx (Inst); Pfizer (Inst); Pfizer/Calithera (Inst); Sanofi (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Incyte
 
Arthur Winer
Consulting or Advisory Role - AstraZeneca
 
Jessie Yanxiang Guo
No Relationships to Disclose
 
Sandra Algaze
No Relationships to Disclose
 
Sandra E Wiley
Employment - MEI Pharma
Travel, Accommodations, Expenses - MEI Pharma
 
Richard Ghalie
Employment - MEI Pharma
Stock and Other Ownership Interests - MEI Pharma; Viracta Therapeutics
Travel, Accommodations, Expenses - MEI Pharma
 
Howard S. Hochster
Stock and Other Ownership Interests - Compass Therapeutics; Processa Pharmaceuticals
Consulting or Advisory Role - Merck; Processa Pharmaceuticals
Other Relationship - seage